Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.

Manoria PC, Chopra HK, Parashar SK, Dutta AL, Pinto B, Mullasari A, Prajapati S.

Indian Heart J. 2013 Dec;65(6):683-90. doi: 10.1016/j.ihj.2013.10.015. Epub 2013 Nov 25. Review.

2.

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125. Review.

3.

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Nov 14;11:140. doi: 10.1186/1475-2840-11-140. Review.

4.

Saroglitazar for the treatment of dyslipidemia in diabetic patients.

Joshi SR.

Expert Opin Pharmacother. 2015 Mar;16(4):597-606. doi: 10.1517/14656566.2015.1009894. Review.

PMID:
25674933
5.
6.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
7.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.

PMID:
23932901
8.

Managing diabetic dyslipidemia: beyond statin therapy.

Neeli H, Gadi R, Rader DJ.

Curr Diab Rep. 2009 Feb;9(1):11-7. Review.

PMID:
19192419
9.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

10.

Managing dyslipidaemia in type 2 diabetes mellitus.

Szalat A, Durst R, Leitersdorf E.

Best Pract Res Clin Endocrinol Metab. 2016 Jun;30(3):431-44. doi: 10.1016/j.beem.2016.05.004. Epub 2016 May 28. Review.

PMID:
27432076
11.

Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.

Matikainen N, Taskinen MR.

Curr Cardiol Rep. 2012 Dec;14(6):721-31. doi: 10.1007/s11886-012-0309-3. Review.

PMID:
22941588
12.

[Diabetic dyslipidaemia and the atherosclerosis].

Márk L, Dani G.

Orv Hetil. 2016 May 8;157(19):746-52. doi: 10.1556/650.2016.30441. Review. Hungarian.

PMID:
27133274
13.

Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient.

Watts GF, Karpe F.

Heart. 2011 Mar;97(5):350-6. doi: 10.1136/hrt.2010.204990. Review.

PMID:
21296781
14.

Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes.

Standl E.

Diab Vasc Dis Res. 2013 Mar;10(2):99-114. doi: 10.1177/1479164112448876. Epub 2012 Jun 20. Review.

PMID:
22718811
15.

Nonstatin therapies for management of dyslipidemia: a review.

Sando KR, Knight M.

Clin Ther. 2015 Oct 1;37(10):2153-79. doi: 10.1016/j.clinthera.2015.09.001. Epub 2015 Sep 26. Review.

PMID:
26412799
16.

[Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian].

Millán J, Alegría E, Guijarro C, Lozano JV, Vitale GC, González-Timón B, González-Juanatey JR.

Med Clin (Barc). 2013 Nov 16;141(10):430-6. doi: 10.1016/j.medcli.2012.09.030. Epub 2012 Dec 12. Spanish.

PMID:
23246165
17.

Do persons with diabetes benefit from combination statin and fibrate therapy?

Rosenblit PD.

Curr Cardiol Rep. 2012 Feb;14(1):112-24. doi: 10.1007/s11886-011-0237-7. Review.

PMID:
22213157
18.

Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence.

Sosale A, Saboo B, Sosale B.

Diabetes Metab Syndr Obes. 2015 Apr 15;8:189-96. doi: 10.2147/DMSO.S49592. eCollection 2015. Review.

19.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165
20.

Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.

Kones R, Rumana U.

Drugs. 2015 Jul;75(11):1201-28. doi: 10.1007/s40265-015-0429-3. Review.

PMID:
26169307

Supplemental Content

Support Center